Industry Collaborations

QHS routinely partners with various industry sponsors to engage in collaborative research.  We typically mine the data in our electronic health record (EPIC) for trends in particular diagnoses, treatments, or outcomes.  Often, we build prediction models linking patient baseline characteristics to important clinical outcomes.  Cleveland Clinic utilizes EPIC My Practice across the entire organization (installed in 1998).  The EHR includes patient demographics, social, medical, family and surgical history, vital signs, imaging data and pathology reports, and rich longitudinal clinical data (diagnosis, procedures, etc.) from both the inpatient and outpatient records.  It contains discrete data linkage with Cleveland Clinic laboratory records, and detailed medication usage information.   In 2014, Cleveland Clinic set a new annual record for outpatient visits (almost 6 million), and has > 1 million active patients (2 or more encounters within the past 12 months). Our partners have included Amgen, AstraZeneca, Merck, and Novo Nordisk.  For more information, please contact Michael Kattan, PhD (Department Chair) at kattanm@ccf.org or Narcis Pasca, MBA (Department Administrator) at pascan@ccf.org.

Publications with Industry Partners

Citation

Year

Wells BJ, Jain A, Arrigain S, Yu C, Rosenkrans WA Jr, Kattan MW. (2008). Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care, 31(12), 2301-2306.

2008

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. (2009). The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol, 46(2), 145-154. doi:10.1007/s00592-008-0090-3

2009

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. (2010). The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care, 33(6), 1224-1229. doi:10.2337/dc10-0017

2010

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. (2012). Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab, 14(9), 803-809.

2012

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS. (2012). The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med, 29(8), 1029-1035. doi:10.1111/j.1464-5491.2012.03577.x

2012

Kumbhani DJ, Wells BJ, Lincoff AM, Jain A, Arrigain S, Yu C, Goormastic M, Ellis SG, Blackstone E, Kattan MW. Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes. Am J Cardiovasc Dis. 2013;3(1):39-52. Epub 2013 Feb 17. PubMed PMID: 23467552; PubMed Central PMCID: PMC3584647.

2013

Wells BJ, Chagin KM, Nowacki AS, Kattan MW. (2013). Strategies for Handling Missing Data in Electronic Health Record Derived Data. eGems, 1(3), 1 - 7.

2013

Wells BJ, Roth R, Nowacki AS, Arrigain S, Yu C, Rosenkrans WA Jr, Kattan MW. (2013). Prediction of morbidity and mortality in patients with type 2 diabetes. PeerJ, 1(e87), 1-13.

2013

Sun GE, Wells BJ, Yip K, Zimmerman R, Raghavan D, Kattan MW, Kashyap SR. (2014) Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2diabetes mellitus. Diabetes Obes Metab. 2014 Mar;16(3):276-83. doi: 10.1111/dom.12231. Epub 2013 Dec 5. PubMed PMID: 24199848.

2014

Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Zimmerman RS. (2015). Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care, 3(1), e000093. doi:10.1136/bmjdrc-2015-000093

2015

Wells BJ, Chagin KM, Li L, Hu B, Yu C, Kattan MW. (2015). Using the landmark method for creating prediction models in large datasets derived from electronic health records. Health Care Management Science, 18(1), 86-92. doi:10.1007/s10729-014-9281-3

2015

Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Zimmerman RS. (2016). Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013. Clin Med Insights Endocrinol Diabetes, 9, 23-30. doi:10.4137/cmed.s39761

2016

Pantalone KM, Wells BJ, Chagin KM, Ejzykowicz F, Yu C, Milinovich A, Bauman JM, Kattan MW, Rajpathak S, Zimmerman RS. (2016). Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. Diabetes Care. doi:10.2337/dc16-0227

2016